Sparsentan Failed to Preserve Kidney Function Over Time in FSGS

(MedPage Today) -- PHILADELPHIA -- Treatment with sparsentan (Filspari) led to no significant differences in estimated glomerular filtration rate (eGFR) slope compared with irbesartan among patients with focal segmental glomerulosclerosis (FSGS...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news